| SpringWorks Therapeutics (SWTX) Reports Q1 Loss, Misses Revenue Estimates |
SpringWorks Therapeutics (SWTX) came out with a quarterly loss of $1.11 per share versus the Zacks Consensus Estimate of a loss of $0.81. This compares to loss of $1.18 per share a year ago. |
zacks.com |
2025-05-09 22:40:33 |
Czytaj oryginał (ang.) |
| SPRINGWORKS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SpringWorks Therapeutics, Inc. - SWTX |
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of SpringWorks Therapeutics, Inc. (NasdaqGS: SWTX) to Merck KGaA, Darmstadt, Germany. Under the terms of the proposed transaction, shareholders of SpringWorks will receive $47.00 in cash for each share of SpringWorks that they own. KSF is seeking to determine whether this consideration and the pro. |
businesswire.com |
2025-04-30 15:57:00 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Believe SpringWorks Therapeutics (SWTX) Could Rally 42.29%: Here's is How to Trade |
The average of price targets set by Wall Street analysts indicates a potential upside of 42.3% in SpringWorks Therapeutics (SWTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2025-04-29 15:01:16 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of SpringWorks Therapeutics, Inc. - SWTX |
NEW YORK , April 28, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating SpringWorks Therapeutics, Inc. (NASDAQ: SWTX ), relating to the proposed merger with Merck KGaA, Darmstadt, Germany. |
prnewswire.com |
2025-04-28 22:14:00 |
Czytaj oryginał (ang.) |
| ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of SpringWorks Therapeutics, Inc. |
NEW YORK , April 28, 2025 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) and its board of directors concerning the proposed acquisition of the company by Merck KGaA. Stockholders will receive $47.00 for each share of SpringWorks Therapeutics stock that they hold. |
prnewswire.com |
2025-04-28 21:33:00 |
Czytaj oryginał (ang.) |
| Shareholder Alert: The Ademi Firm Investigates Whether SpringWorks Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders |
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating SpringWorks (Nasdaq: SWTX) for possible breaches of fiduciary duty and other violations of law in its transaction with Merck. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, shareholders of SpringWorks will receive only $47 per share in cash, which represents an equity value of. |
businesswire.com |
2025-04-28 14:43:00 |
Czytaj oryginał (ang.) |
| Germany's Merck Agrees to Buy US Biotech SpringWorks Therapeutics for Almost $4B |
German drug company Merck KGaA said Monday it has struck a deal to buy U.S. biotech firm SpringWorks Therapeutics (SWTX) for around $3.9 billion, expanding its portfolio of rare disease and cancer treatments. |
investopedia.com |
2025-04-28 11:25:55 |
Czytaj oryginał (ang.) |
| SWTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of SpringWorks Therapeutics, Inc. Is Fair to Shareholders |
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) to Merck KGaA, Darmstadt, Germany for $47.00 per share in cash is fair to SpringWorks shareholders. Halper Sadeh encourages SpringWorks shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigati. |
businesswire.com |
2025-04-28 10:59:00 |
Czytaj oryginał (ang.) |
| Merck KGaA swoops for US group SpringWorks in $3.4bn deal |
Germany's Merck KGaA has agreed to acquire US biotech firm SpringWorks Therapeutics for $3.9 billion in cash. The deal, announced on Monday, values SpringWorks at $47 a share and reflects an enterprise value of $3.4 billion after accounting for the company's cash reserves. |
proactiveinvestors.co.uk |
2025-04-28 06:58:56 |
Czytaj oryginał (ang.) |
| Germany's Merck Set to Buy SpringWorks in $3.9 Billion Deal |
The deal to acquire the U.S. biopharmaceutical company confirms an earlier report in The Wall Street Journal. |
wsj.com |
2025-04-28 06:33:00 |
Czytaj oryginał (ang.) |
| Germany's Merck KGaA in $3.9 bln deal to acquire US biotech firm SpringWorks |
German healthcare and materials group Merck KGaA said on Monday it struck a deal to acquire U.S. biotech firm SpringWorks Therapeutics for an equity value of $3.9 billion to boost its cancer drug business. |
reuters.com |
2025-04-28 06:21:41 |
Czytaj oryginał (ang.) |
| Merck KGaA, Darmstadt, Germany to Acquire SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business |
– Purchase price of $47 per share in cash represents an equity value of approximately $3.9 billion, or an enterprise value of $3.4 billion (€3.0 billion) – – Planned acquisition will immediately add revenue and accelerate mid- to long-term growth for Merck KGaA, Darmstadt, Germany's Healthcare business – – SpringWorks Therapeutics is a U.S. biopharmaceutical company with a first-in-class, systemic standard-of-care therapy in adults with desmoid tumors and the first and only approved therapy for adults and children with neurofibromatosis type 1-associated plexiform neurofibromas – – Planned acquisition will strengthen the presence of Merck KGaA, Darmstadt, Germany's Healthcare business in the United States and expand reach of SpringWorks' therapeutic innovations to more patients with rare tumors worldwide – STAMFORD, Conn., April 28, 2025 (GLOBE NEWSWIRE) -- Merck KGaA, Darmstadt, Germany (DAX: MRK), a leading science and technology company, and SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced the companies have entered into a definitive agreement for Merck KGaA, Darmstadt, Germany to acquire SpringWorks. |
globenewswire.com |
2025-04-28 06:13:00 |
Czytaj oryginał (ang.) |
| Merck KGaA, Darmstadt, Germany, to Acquire US Biopharma Company SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business |
DARMSTADT, Germany--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany (DAX: MRK), a leading science and technology company, and SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a Stamford, Connecticut-based commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced the companies have entered into a definitive agreement for Merck KGaA, Darmstadt, Germany, to acquire SpringWorks. The purchase price of $47 per share in cash represents an equity value of appr. |
businesswire.com |
2025-04-28 06:11:00 |
Czytaj oryginał (ang.) |
| SpringWorks Therapeutics Announces Expected CHMP Opinion in Q2 2025 for Nirogacestat for the Treatment of Adults with Desmoid Tumors in the European Union |
STAMFORD, Conn., April 27, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that the Company anticipates the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) will adopt an opinion on the marketing authorization application (MAA) for nirogacestat, an oral gamma secretase inhibitor, for the treatment of adults with desmoid tumors in the second quarter of 2025. |
globenewswire.com |
2025-04-27 14:35:00 |
Czytaj oryginał (ang.) |
| SpringWorks Therapeutics (SWTX) Soars 9.0%: Is Further Upside Left in the Stock? |
SpringWorks Therapeutics (SWTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. |
zacks.com |
2025-04-25 13:10:48 |
Czytaj oryginał (ang.) |
| Germany's Merck nears roughly $3.5 billion deal for SpringWorks, WSJ reports |
Germany's Merck KGaA is nearing a roughly $3.5 billion deal for SpringWorks Therapeutics , the Wall Street Journal reported on Thursday, citing people familiar with the matter. |
reuters.com |
2025-04-24 19:20:29 |
Czytaj oryginał (ang.) |
| Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks |
The two companies have been talking for months about a deal |
wsj.com |
2025-04-24 19:05:00 |
Czytaj oryginał (ang.) |
| SpringWorks Therapeutics: Promising Launches, Expanding Pipeline, And M&A Buzz |
SpringWorks Therapeutics portfolio features Ogsiveo for desmoid tumors and Gomekli for NF1‑plexiform neurofibromas. In fact, Ogsiveo's revenues alone reached $172 million in 2024, supported by orphan drug designations in the US and EU. Similarly, Gomekli is the first FDA-approved MEK inhibitor for NF1‑plexiform neurofibromas, which targets both adults and children. |
seekingalpha.com |
2025-03-11 11:15:00 |
Czytaj oryginał (ang.) |
| SpringWorks' Q4 Loss Wider Than Expected, Revenues Beat Estimates |
SWTX reports mixed fourth-quarter 2024 results. Its newly approved desmoid tumor drug, Ogsiveo, witnesses a strong launch. |
zacks.com |
2025-02-21 13:45:59 |
Czytaj oryginał (ang.) |
| SpringWorks Therapeutics (SWTX) Reports Q4 Loss, Tops Revenue Estimates |
SpringWorks Therapeutics (SWTX) came out with a quarterly loss of $1.04 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to loss of $1.44 per share a year ago. |
zacks.com |
2025-02-20 10:46:08 |
Czytaj oryginał (ang.) |
| SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates |
– Achieved $61.5 million and $172.0 million in fourth quarter and full year 2024 OGSIVEO ® (nirogacestat) U.S. net product revenues, respectively – |
globenewswire.com |
2025-02-20 08:30:00 |
Czytaj oryginał (ang.) |
| SpringWorks Therapeutics and Jewelry Designer Jennifer Fisher Team Up to Encourage People with Desmoid Tumors to Take Action Before Their Tumor Takes Over |
- Educational campaign aims to raise awareness and drive conversation about desmoid tumors, the devastating impact they have on patients' lives - STAMFORD, Conn. , Feb. 19, 2025 /PRNewswire/ -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, and Jennifer Fisher, jewelry designer and desmoid tumor patient advocate, are collaborating to increase understanding of desmoid tumors as well as to encourage patients to find a specialist, like an oncologist with experience treating desmoid tumors who can discuss available treatment options to manage their desmoid tumor. |
prnewswire.com |
2025-02-19 10:00:00 |
Czytaj oryginał (ang.) |
| Onco360 Has Been Selected as a National Specialty Pharmacy Partner for GOMEKLI™ (mirdametinib), Manufactured By SpringWorks Therapeutics |
LOUISVILLE, Ky., Feb. 17, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation's leading independent specialty pharmacy, has been selected as a national pharmacy partner by SpringWorks Therapeutics, Inc. for GOMEKLI (mirdametinib). The Food & Drug Administration approved GOMEKLI for the treatment of adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete resection.1 |
globenewswire.com |
2025-02-17 18:05:00 |
Czytaj oryginał (ang.) |
| SpringWorks Therapeutics (SWTX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release |
SpringWorks Therapeutics (SWTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-02-13 13:06:15 |
Czytaj oryginał (ang.) |
| UPDATE: SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN |
– GOMEKLI is the first and only medicine approved for both adults and children with NF1-PN – – Approval based on positive data from Phase 2b ReNeu trial, which showed GOMEKLI treatment resulted in robust ORR, deep and durable reductions in tumor volume, and a manageable safety profile – – SpringWorks granted rare pediatric disease priority review voucher by the FDA – Photos accompanying this announcement are available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/8eb8effc-49a5-4b24-911f-d3e6dfa9c8a9 https://www.globenewswire.com/NewsRoom/AttachmentNg/f1041678-3f79-43b7-a101-2390fb8cb86b https://www.globenewswire.com/NewsRoom/AttachmentNg/7d8cb318-e5f8-4944-8736-24cb19a5dec9 https://www.globenewswire.com/NewsRoom/AttachmentNg/072d748b-3237-48ad-8d83-1c6c23dda65f STAMFORD, Conn., Feb. 11, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that the U.S. Food and Drug Administration (FDA) has approved GOMEKLI™ (mirdametinib), SpringWorks' MEK inhibitor, for the treatment of adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete resection.1 With the approval, SpringWorks was granted a rare pediatric disease priority review voucher (PRV) by the FDA. |
globenewswire.com |
2025-02-11 22:20:00 |
Czytaj oryginał (ang.) |
| SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN |
– GOMEKLI is the first and only medicine approved for both adults and children with NF1-PN – – Approval based on positive data from Phase 2b ReNeu trial, which showed GOMEKLI treatment resulted in robust ORR, deep and durable reductions in tumor volume, and a manageable safety profile – – SpringWorks granted rare pediatric disease priority review voucher by the FDA – Photos accompanying this announcement are available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/8eb8effc-49a5-4b24-911f-d3e6dfa9c8a9 https://www.globenewswire.com/NewsRoom/AttachmentNg/f1041678-3f79-43b7-a101-2390fb8cb86b https://www.globenewswire.com/NewsRoom/AttachmentNg/7d8cb318-e5f8-4944-8736-24cb19a5dec9 https://www.globenewswire.com/NewsRoom/AttachmentNg/072d748b-3237-48ad-8d83-1c6c23dda65f STAMFORD, Conn., Feb. 11, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that the U.S. Food and Drug Administration (FDA) has approved GOMEKLI™ (mirdametinib), SpringWorks' MEK inhibitor, for the treatment of adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete resection.1 With the approval, SpringWorks was granted a rare pediatric disease priority review voucher (PRV) by the FDA. |
globenewswire.com |
2025-02-11 19:27:00 |
Czytaj oryginał (ang.) |
| SpringWorks Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 20, 2025 |
STAMFORD, Conn., Jan. 30, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, February 20, 2025 to report its fourth quarter and full year financial results and discuss recent business updates. |
globenewswire.com |
2025-01-30 09:00:00 |
Czytaj oryginał (ang.) |
| SWTX Announces 2024 Preliminary Results, 2025 Goals, Stock Down |
SpringWorks reports preliminary fourth-quarter and full-year 2024 product revenues. It also provides updates across the commercial portfolio and other pipelines. |
zacks.com |
2025-01-14 15:00:42 |
Czytaj oryginał (ang.) |
| SpringWorks Therapeutics Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates at 43rd Annual J.P. Morgan Healthcare Conference |
– Achieved $61.5 million and $172.0 million in preliminary fourth quarter and full year 2024 OGSIVEO ® (nirogacestat) U.S. net product revenues, respectively – |
globenewswire.com |
2025-01-13 08:30:00 |
Czytaj oryginał (ang.) |
| SpringWorks: PDUFA Review Date Could Lead To Next Approved Pipeline Candidate |
SpringWorks has shown strong revenue growth with OGSIVEO, achieving a 23% increase from Q2 of 2024 to Q3 of 2024, and potential EMA approval if it could boost sales further. Mirdametinib, a MEK inhibitor for NF1-PN, has a PDUFA date of February 28th of 2025, and could unlock significant shareholder value if approved. Results from phase 1b study using brimarafenib to treat patients with MAPK mutant solid tumors are expected to be released in the 2nd half of 2025. |
seekingalpha.com |
2025-01-13 07:56:55 |
Czytaj oryginał (ang.) |
| Strength Seen in SpringWorks Therapeutics (SWTX): Can Its 6.0% Jump Turn into More Strength? |
SpringWorks Therapeutics (SWTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. |
zacks.com |
2025-01-08 06:46:12 |
Czytaj oryginał (ang.) |
| SpringWorks Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
STAMFORD, Conn., Jan. 03, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that Saqib Islam, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 11:15 a.m. PT. |
globenewswire.com |
2025-01-03 08:30:00 |
Czytaj oryginał (ang.) |
| SpringWorks: With Catalyst On The Horizon And Growing Sales, 2025 Looks Great |
SpringWorks Therapeutics shows promising growth with their first approved drug and an imminent second approval for mirdametinib in NF1 treatment. SWTX's financials reveal strong cash reserves and growing sales, though they remain unprofitable, with a net loss of $53.5 million in Q3 2024. Strengths include sustained sales growth and potential back-to-back drug approvals, but risks involve market competition and aggressive goal setting. |
seekingalpha.com |
2024-12-31 10:30:00 |
Czytaj oryginał (ang.) |
| Tarsus Pharmaceuticals & SpringWorks Therapeutics: Jonathan Faison's Top 2 Picks |
Jonathan Faison runs the ROTY Biotech Community. Why he's high on Tarsus Pharmaceuticals and his #1 holding, SpringWorks Therapeutics. |
seekingalpha.com |
2024-12-15 16:00:00 |
Czytaj oryginał (ang.) |
| SpringWorks Therapeutics (SWTX) Up 14.5% Since Last Earnings Report: Can It Continue? |
SpringWorks Therapeutics (SWTX) reported earnings 30 days ago. What's next for the stock? |
zacks.com |
2024-12-12 14:36:17 |
Czytaj oryginał (ang.) |
| SpringWorks Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference |
STAMFORD, Conn., Nov. 26, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that management will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference, taking place in Coral Gables, Florida on Tuesday, December 3, 2024 at 12:30 p.m. ET. |
globenewswire.com |
2024-11-26 09:00:00 |
Czytaj oryginał (ang.) |
| Does SpringWorks Therapeutics (SWTX) Have the Potential to Rally 92.68% as Wall Street Analysts Expect? |
The mean of analysts' price targets for SpringWorks Therapeutics (SWTX) points to a 92.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
zacks.com |
2024-11-14 12:56:10 |
Czytaj oryginał (ang.) |
| SpringWorks' Q3 Loss Narrower Than Expected, Revenues Miss Mark |
SWTX reports mixed third-quarter 2024 results. Its newly approved desmoid tumor drug, Ogsiveo, witnesses a strong launch. |
zacks.com |
2024-11-13 13:51:09 |
Czytaj oryginał (ang.) |
| SpringWorks Therapeutics, Inc. (SWTX) Q3 2024 Earnings Call Transcript |
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX ) Q3 2024 Earnings Call November 12, 2024 8:30 AM ET Company Participants Kim Diamond - Vice President, Corporate Communications Saqib Islam - Chief Executive Officer Bhavesh Ashar - Chief Commercial Officer Jim Cassidy - Chief Medical Officer Francis Perier - Chief Financial Officer Badreddin Edris - Chief Operating Officer Conference Call Participants Anupam Rama - JPMorgan Peter Lawson - Barclays Corinne Johnson - Goldman Sachs David Nierengarten - Wedbush Securities Alec Stranahan - Bank of America Operator Good morning. My name is Tanya, and I will be your conference operator today. |
seekingalpha.com |
2024-11-12 15:20:28 |
Czytaj oryginał (ang.) |
| SpringWorks Therapeutics to Participate in the Jefferies London Healthcare Conference |
STAMFORD, Conn., Nov. 12, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference, taking place in London, United Kingdom on Tuesday, November 19, 2024 at 10:30 a.m. ET. |
globenewswire.com |
2024-11-12 11:25:00 |
Czytaj oryginał (ang.) |
| SpringWorks Therapeutics (SWTX) Reports Q3 Loss, Lags Revenue Estimates |
SpringWorks Therapeutics (SWTX) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to loss of $1.27 per share a year ago. |
zacks.com |
2024-11-12 10:45:16 |
Czytaj oryginał (ang.) |
| SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights |
– Achieved $49.3 million in OGSIVEO ® (nirogacestat) net product revenue in the third quarter – |
globenewswire.com |
2024-11-12 08:30:00 |
Czytaj oryginał (ang.) |
| SpringWorks Therapeutics Announces Mirdametinib Data to be Presented at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting |
– Data from the pivotal Phase 2b ReNeu trial demonstrate that patients with NF1-PN achieved deep responses and improvements in health-related quality of life over the course of mirdametinib treatment – |
globenewswire.com |
2024-11-11 09:00:00 |
Czytaj oryginał (ang.) |
| SpringWorks Therapeutics Announces Publication of the Pivotal Phase 2b ReNeu Trial Evaluating Mirdametinib in Adults and Children with NF1-PN in the Journal of Clinical Oncology |
– Mirdametinib treatment demonstrated significant confirmed objective response rates and a manageable safety profile in adults and children with NF1-PN – |
globenewswire.com |
2024-11-11 08:30:00 |
Czytaj oryginał (ang.) |
| SpringWorks Therapeutics Announces Long-Term Efficacy and Safety Data from Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors to be Presented at the Connective Tissue Oncology Society (CTOS) 2024 Annual Meeting |
– Long-term follow-up data highlight further reductions in tumor size, increase in ORR with additional CRs, sustained improvement in desmoid tumor symptoms, and consistent safety profile, now with a median duration of therapy of approximately 3 years – |
globenewswire.com |
2024-11-07 08:30:00 |
Czytaj oryginał (ang.) |
| SpringWorks Therapeutics to Participate in Guggenheim's Inaugural Healthcare Innovation Conference |
STAMFORD, Conn., Nov. 05, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that management will participate in a fireside chat at Guggenheim's Inaugural Healthcare Innovation Conference, taking place in Boston, Massachusetts on Wednesday, November 13, 2024 at 1:00 p.m. ET. |
globenewswire.com |
2024-11-05 09:00:00 |
Czytaj oryginał (ang.) |
| SpringWorks Therapeutics Merits A Speculative Buy |
Since we last visited with SpringWorks Therapeutics, Inc. in the summer of 2023, the company has garnered its first FDA approval. That drug has seen encouraging initial sales, and management recently submitted a marketing application for a second candidate. The stock has pulled back recently, even as SpringWorks has funding in place to get the company to profitability in the years ahead. |
seekingalpha.com |
2024-11-04 14:17:12 |
Czytaj oryginał (ang.) |
| SpringWorks Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024 |
STAMFORD, Conn., Oct. 22, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Tuesday, November 12, 2024 to report its third quarter financial results and discuss recent business updates. |
globenewswire.com |
2024-10-22 11:00:00 |
Czytaj oryginał (ang.) |
| Why Is SpringWorks Therapeutics (SWTX) Up 11.7% Since Last Earnings Report? |
SpringWorks Therapeutics (SWTX) reported earnings 30 days ago. What's next for the stock? |
zacks.com |
2024-09-06 16:38:01 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Predict a 61.05% Upside in SpringWorks Therapeutics (SWTX): Here's What You Should Know |
The mean of analysts' price targets for SpringWorks Therapeutics (SWTX) points to a 61.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
zacks.com |
2024-09-05 14:57:04 |
Czytaj oryginał (ang.) |
| SWTX's NDA for Rare Tumor Drug Gets Priority Review From FDA |
The FDA accepts and grants priority review to SpringWorks' NDA for mirdametinib for treating neurofibromatosis type 1-associated plexiform neurofibromas. |
zacks.com |
2024-08-29 16:55:19 |
Czytaj oryginał (ang.) |